Global Kinetics adds former EMA head to board


By Dylan Bushell-Embling
Monday, 10 November, 2014

Global Kinetics Corporation has appointed former EMA chief Dr Thomas Lönngren to its board, as it seeks to commercialise its Parkinson’s KinetiGraph (PKG) technology.

Lönngren is a Swedish regulatory affairs veteran with a background in health systems, drug and medical device regulations.

Global Kinetics has made the appointment as part of its EU expansion strategy for PKG, a device for monitoring Parkinson’s symptoms and helping to optimise treatment options.

The company also revealed it has been awarded a key European patent covering its intellectual property. The patent covers the company’s ability to record, measure and assess clinical movement data using the PKG technology, and the mathematical algorithms associated with the data analysis.

Global Kinetics CEO Andrew Maxwell said the two developments will be key to the company’s long-term plans for the device.

“Dr Lönngren has an impeccable background in health systems, drug, medical device regulations and in working with international government and industry stakeholders at the highest levels,” he said.

“We expect his expertise to prove invaluable as we deliver value for people with Parkinson’s disease, clinicians, governments and commercial stakeholders worldwide.”

The PKG already has clearance from the FDA, EMA and TGA.

Related News

Shingles vaccine may reduce risk of heart attack and stroke 

Vaccination with either the recombinant herpes zoster vaccine or the live-attenuated zoster...

Perioperative trial offers insights into brain cancer treatment

Victorian brain cancer researchers have used an innovative process to learn how a new drug...

New molecular mechanism found for depression

Depression may not only result from simple neuronal damage but can also arise from the...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd